ABCL

Company Overview — What Does AbCellera Biologics Inc. Do?

AbCellera Biologics Inc. develops antibody discovery platform. Its full-stack, artificial intelligence-powered antibody discovery platform searches and analyzes the database of natural immune systems to find antibodies that could be developed as drugs. As of December 31, 2021, the company had 156 discovery programs that are either completed, in progress, or under contract with 36 partners. AbCellera Biologics Inc. has a research collaboration and license agreement with Eli Lilly and Company. The company was incorporated in 2012 and is headquartered in Vancouver, Canada. AbCellera Biologics Inc. (ABCL) is classified as a small-cap stock in the Healthcare sector, specifically within the Pharmaceutical Products industry. The company is led by CEO Carl Lars G. Hansen and employs approximately 500 people. With a market capitalization of $1.1B, ABCL is one of the notable companies in the Healthcare sector.

AbCellera Biologics Inc. (ABCL) Stock Rating — Reduce (April 2026)

As of April 2026, AbCellera Biologics Inc. receives a Reduce rating with a composite score of 35.0/100 and 2 out of 5 stars from the Blank Capital Research quantitative model.ABCL ranks #2,305 out of 4,446 stocks in our coverage universe. Within the Healthcare sector, AbCellera Biologics Inc. ranks #273 of 838 stocks, placing it in the upper half of its Healthcare peers. The rating is generated by a multi-factor model that weighs quality (30%), momentum (25%), value (15%), investment (10%), stability (10%), and short interest (10%).

ABCL Stock Price and 52-Week Range

AbCellera Biologics Inc. (ABCL) currently trades at $3.56. The stock gained $0.12 (3.5%) in the most recent trading session. The 52-week high for ABCL is $6.51, which means the stock is currently trading -45.4% from its annual peak. The 52-week low is $1.89, putting the stock 88.3% above its annual trough. Recent trading volume was 2.4M shares, reflecting moderate market activity.

Is ABCL Overvalued or Undervalued? — Valuation Analysis

AbCellera Biologics Inc. (ABCL) carries a value factor score of 20/100 in the Blank Capital model, signaling premium valuation that prices in significant future growth. The price-to-book ratio stands at 1.03x, versus the sector average of 2.75x. The price-to-sales ratio is 27.20x, compared to 1.66x for the average Healthcare stock.

At current multiples, AbCellera Biologics Inc. trades at a premium to most Healthcare peers. This elevated valuation may be justified if the company can sustain above-average growth rates and profitability, but it also creates downside risk if earnings disappoint expectations.

AbCellera Biologics Inc. Profitability — ROE, Margins, and Quality Score

AbCellera Biologics Inc. (ABCL) earns a quality factor score of 34/100, signaling below-average profitability metrics relative to the broader market. The return on equity (ROE) is -19.5%, compared to the Healthcare sector average of -43.5%, which is below typical expectations for high-quality companies. Return on assets (ROA) comes in at -13.9% versus the sector average of -33.1%.

On a margin basis, AbCellera Biologics Inc. reports gross margins of 100.0%, compared to 71.5% for the sector. The operating margin is -1015.3% (sector: -66.1%). Net profit margin stands at -675.9%, versus -58.7% for the average Healthcare stock. Revenue growth is running at 22.3% on a trailing basis, compared to 10.6% for the sector. Profitability is below benchmark levels, which may reflect industry headwinds, elevated reinvestment, or structural challenges.

ABCL Debt, Balance Sheet, and Financial Health

AbCellera Biologics Inc. has a debt-to-equity ratio of 40.0%, compared to the Healthcare sector average of 32.0%. The low leverage indicates a conservative balance sheet with significant financial flexibility. The current ratio is 11.32x, indicating strong short-term liquidity. Total debt on the balance sheet is $0. Cash and equivalents stand at $83M.

ABCL has a beta of 1.43, meaning it is more volatile than the broader market — a $10,000 investment in ABCL would be expected to move 43.0% more than the S&P 500 on any given day. The stability factor score for AbCellera Biologics Inc. is 32/100, suggesting elevated price swings that may be unsuitable for conservative portfolios.

AbCellera Biologics Inc. Revenue and Earnings History — Quarterly Trend

In TTM 2026, AbCellera Biologics Inc. reported revenue of $37M and earnings per share (EPS) of $-0.49. Net income for the quarter was $-189M. Gross margin was 100.0%. Operating income came in at $-282M.

In FY 2025, AbCellera Biologics Inc. reported revenue of $75M and earnings per share (EPS) of $-0.49. Net income for the quarter was $-146M. Revenue grew 160.6% year-over-year compared to FY 2024. Operating income came in at $-217M.

In Q3 2025, AbCellera Biologics Inc. reported revenue of $9M and earnings per share (EPS) of $-0.19. Net income for the quarter was $-57M. Revenue grew 37.6% year-over-year compared to Q3 2024. Operating income came in at $-76M.

In Q2 2025, AbCellera Biologics Inc. reported revenue of $17M and earnings per share (EPS) of $-0.12. Net income for the quarter was $-35M. Revenue grew 133.3% year-over-year compared to Q2 2024. Operating income came in at $-50M.

Over the past 8 quarters, AbCellera Biologics Inc. has demonstrated a growth trajectory, with revenue expanding from $7M to $37M. Investors analyzing ABCL stock should weigh these quarterly trends alongside the valuation and quality metrics discussed above.

ABCL Dividend Yield and Income Analysis

AbCellera Biologics Inc. (ABCL) does not currently pay a dividend. This is common among smaller companies in the Pharmaceutical Products industry that prefer to reinvest cash flows into business expansion rather than returning capital to shareholders. Income-focused investors looking for Healthcare dividend stocks may want to explore other Healthcare stocks or use the stock screener to filter by dividend yield.

ABCL Momentum and Technical Analysis Profile

AbCellera Biologics Inc. (ABCL) has a momentum factor score of 47/100, reflecting neutral trend characteristics. The stock is neither significantly outperforming nor underperforming the broader market on a momentum basis. The investment factor score is 25/100, which measures capital allocation efficiency and asset growth patterns. The short interest score of 47/100 reflects moderate short selling activity.

ABCL vs Competitors — Healthcare Sector Ranking and Peer Comparison

Within the Healthcare sector, AbCellera Biologics Inc. (ABCL) ranks #273 out of 838 stocks based on the Blank Capital composite score. This places ABCL in the upper half of all Healthcare stocks in our coverage universe. Key competitors and sector peers include ASTRAZENECA PLC (AZN) with a score of 61.4/100, Sol-Gel Technologies Ltd. (SLGL) with a score of 56.6/100, VIEMED HEALTHCARE, INC. (VMD) with a score of 53.4/100, Innoviva, Inc. (INVA) with a score of 52.7/100, and JOHNSON & JOHNSON (JNJ) with a score of 51.7/100.

Comparing ABCL against the S&P 500 benchmark is also instructive for understanding relative performance. Investors can view the full ABCL vs S&P 500 (SPY) comparison to assess how AbCellera Biologics Inc. stacks up against the broader market across all factor dimensions.

ABCL Next Earnings Date

No upcoming earnings date has been announced for AbCellera Biologics Inc. (ABCL) at this time. Check the earnings calendar for the latest scheduling updates across all stocks in our coverage universe.

Should You Buy ABCL? — Investment Thesis Summary

The quantitative profile for AbCellera Biologics Inc. suggests caution. The quality score of 34/100 flags below-average profitability. The value score of 20/100 indicates premium valuation. High volatility (stability score 32/100) increases portfolio risk.

In summary, AbCellera Biologics Inc. (ABCL) earns a Reduce rating with a composite score of 35.0/100 as of April 2026. The rating is derived from the Blank Capital Research methodology, which combines six factor dimensions into a single quantitative ranking. Investors should consider these quantitative signals alongside their own fundamental research, risk tolerance, and investment time horizon before making buy or sell decisions on ABCL stock.

Related Resources for ABCL Investors

Explore more research and tools: ABCL vs S&P 500 comparison, top Healthcare stocks, stock screener, our methodology, quality factor explained, value factor explained, momentum factor explained. Compare ABCL head-to-head with peers: ABCL vs AZN, ABCL vs SLGL, ABCL vs VMD.